newsfilter
← Latest News
GlobeNewswire·

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with